Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
Myriad Genetics Inc. (NASDAQ: MYGN) has announced a strategic partnership with jscreen™ to advance health equity and genetic testing access. This collaboration combines Myriad's MyRisk® with RiskScore® and Foresight® Carrier Screen with jscreen's education and genetic care navigation program. The partnership aims to reach hundreds of thousands of high-risk adults across the United States through targeted outreach, educational events, and in-person genetic screenings.
The collaboration focuses on serving individuals of Jewish descent, emphasizing outreach, education, and testing convenience. jscreen's platform allows consumers to order genetic test kits online, provide saliva samples, and send them back to Myriad's lab for processing. This partnership aligns with both organizations' missions to provide preventative genetic care and improve access to carrier screening and hereditary cancer testing.
Myriad Genetics Inc. (NASDAQ: MYGN) ha annunciato una partnership strategica con jscreen™ per promuovere l'equità sanitaria e l'accesso ai test genetici. Questa collaborazione combina il MyRisk® con RiskScore® e il Foresight® Carrier Screen di Myriad con il programma educativo e di navigazione nella cura genetica di jscreen. L'obiettivo della partnership è raggiungere centinaia di migliaia di adulti ad alto rischio negli Stati Uniti attraverso campagne mirate, eventi educativi e screening genetici in persona.
La collaborazione si concentra sul servire individui di origine ebraica, enfatizzando l'importanza della sensibilizzazione, dell'educazione e della comodità nei test. La piattaforma di jscreen consente ai consumatori di ordinare kit di test genetici online, fornire campioni di saliva e inviarli al laboratorio di Myriad per l'analisi. Questa partnership è in linea con le missioni di entrambe le organizzazioni di fornire assistenza genetica preventiva e migliorare l'accesso allo screening per i portatori e ai test sul cancro ereditario.
Myriad Genetics Inc. (NASDAQ: MYGN) ha anunciado una asociación estratégica con jscreen™ para avanzar en la equidad en salud y el acceso a pruebas genéticas. Esta colaboración combina MyRisk® con RiskScore® y Foresight® Carrier Screen de Myriad con el programa de educación y navegación en cuidado genético de jscreen. La asociación tiene como objetivo alcanzar a cientos de miles de adultos de alto riesgo en los Estados Unidos a través de acciones dirigidas, eventos educativos y pruebas genéticas en persona.
La colaboración se enfoca en atender a personas de ascendencia judía, enfatizando la sensibilización, la educación y la conveniencia de las pruebas. La plataforma de jscreen permite a los consumidores pedir kits de pruebas genéticas en línea, proporcionar muestras de saliva y enviarlas de vuelta al laboratorio de Myriad para su procesamiento. Esta asociación está alineada con las misiones de ambas organizaciones para brindar atención genética preventiva y mejorar el acceso al screening de portadores y a las pruebas de cáncer hereditario.
Myriad Genetics Inc. (NASDAQ: MYGN)는 jscreen™과 전략적 파트너십을 맺고 건강 형평성과 유전자 검사 접근성을 향상시키겠다고 발표했습니다. 이 협력은 Myriad의 MyRisk®와 RiskScore®, Foresight® Carrier Screen을 jscreen의 교육 및 유전자 치료 탐색 프로그램과 결합합니다. 파트너십의 목표는 미국 전역의 수십만 고위험 성인에게 목표 지향적인 접근, 교육 이벤트 및 대면 유전자 검사를 통해 도달하는 것입니다.
이 협력은 유대인 혈통의 개인을 돕는 것에 중점을 두며, outreach, 교육 및 검사 편리성을 강조합니다. jscreen의 플랫폼은 소비자가 온라인으로 유전자 검사 키트를 주문하고, 침 샘플을 제공하고, 이를 Myriad의 실험실에 보내 처리할 수 있게 합니다. 이 파트너십은 예방적 유전자 치료를 제공하고, 유전자 검사를 위한 접근을 개선하는 두 조직의 사명에 부합합니다.
Myriad Genetics Inc. (NASDAQ: MYGN) a annoncé un partenariat stratégique avec jscreen™ pour faire avancer l'équité en santé et l'accès aux tests génétiques. Cette collaboration combine MyRisk® avec RiskScore® et Foresight® Carrier Screen de Myriad avec le programme de navigation éducative et de soins génétiques de jscreen. Le partenariat vise à atteindre des centaines de milliers d'adultes à haut risque à travers les États-Unis grâce à des actions ciblées, des événements éducatifs et des dépistages génétiques en personne.
La collaboration se concentre sur le service des individus d'origine juive, mettant l'accent sur la sensibilisation, l'éducation et la commodité des tests. La plateforme de jscreen permet aux consommateurs de commander des kits de tests génétiques en ligne, de fournir des échantillons de salive et de les envoyer de retour au laboratoire de Myriad pour traitement. Ce partenariat est en accord avec les missions des deux organisations visant à fournir des soins génétiques préventifs et à améliorer l'accès au dépistage des porteurs et aux tests de cancer héréditaire.
Myriad Genetics Inc. (NASDAQ: MYGN) hat eine strategische Partnerschaft mit jscreen™ bekannt gegeben, um die gesundheitliche Chancengleichheit und den Zugang zu genetischen Tests zu verbessern. Diese Zusammenarbeit kombiniert Myriads MyRisk® mit RiskScore® und Foresight® Carrier Screen mit jscreen's Bildungs- und genetischen Beratungsprogramm. Das Ziel der Partnerschaft ist es, hunderttausende von Hochrisiko-Erwachsenen in den Vereinigten Staaten durch gezielte Maßnahmen, Bildungsevents und persönliche genetische Screenings zu erreichen.
Die Zusammenarbeit konzentriert sich darauf, Personen jüdischer Abstammung zu bedienen und betont die Notwendigkeit von Sensibilisierung, Bildung und Prüfungsbequemlichkeit. Die Plattform von jscreen ermöglicht es den Verbrauchern, genetische Testkits online zu bestellen, Speichelproben bereitzustellen und diese zur Verarbeitung an Myriads Labor zurückzusenden. Diese Partnerschaft steht im Einklang mit den Missionen beider Organisationen, eine präventive genetische Versorgung bereitzustellen und den Zugang zu Trägerscreenings und erblichen Krebstests zu verbessern.
- Strategic partnership with jscreen™ to expand genetic testing access
- Potential to reach hundreds of thousands of high-risk adults across the US
- Combines Myriad's genetic testing products with jscreen's education and care navigation program
- Focus on serving individuals of Jewish descent, a high-risk population
- Alignment of missions to provide preventative genetic care and improve access
- None.
Insights
This strategic partnership between Myriad Genetics and jscreen™ represents a significant step towards expanding access to genetic testing, particularly for high-risk populations. The collaboration leverages Myriad's established genetic tests with jscreen's education and outreach capabilities, potentially reaching hundreds of thousands of individuals.
Key points to consider:
- The partnership focuses on hereditary cancer and reproductive genetics, targeting a important healthcare niche.
- It addresses health equity issues by improving access to genetic testing for underserved populations.
- The collaboration may lead to increased test volumes for Myriad, potentially boosting revenue in the long term.
- Enhanced early detection rates could positively impact patient outcomes and healthcare costs.
While this partnership shows promise for expanding Myriad's market reach and improving public health, its immediate financial impact may be Investors should monitor future updates on test volumes and revenue growth resulting from this initiative.
This partnership aligns with growing trends in personalized medicine and preventative healthcare. Key market implications include:
- Potential for market expansion as Myriad taps into jscreen's network and outreach capabilities.
- Enhanced brand visibility through association with jscreen's trusted platform.
- Possible increase in test adoption rates due to improved education and accessibility.
- Strengthened position in the competitive genetic testing landscape.
The consumer-initiated platform model could drive growth by reducing barriers to genetic testing. However, the financial impact may take time to materialize as awareness and adoption grow gradually. Investors should consider this a long-term strategic move rather than an immediate revenue driver. The partnership's success will depend on effective execution and consumer uptake, which should be closely monitored in future quarters.
SALT LAKE CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a strategic partnership with jscreen™, a national organization that delivers education and access to preventative genetic testing with a focus on high-risk populations.
The collaboration combines the strengths of Myriad’s high-quality hereditary cancer and reproductive genetics products, MyRisk® with RiskScore® and Foresight® Carrier Screen, with jscreen’s trusted education and genetic care navigation program. Through the partnership, the jscreen program intends to reach hundreds of thousands of high-risk adults across the United States through targeted outreach, educational events and in-person genetic screenings.
“Mutations in BRCA genes raise a person's risk for breast cancer, ovarian and other cancers, which is why our collaboration with jscreen is deeply rooted in our mutual commitments to prioritizing patient care and ensuring equitable access to high-quality genetic testing, which can help guide more informed medical decision-making and personalized care,” said Melissa Gonzales, President of Women’s Health, Myriad Genetics. “This partnership helps us better serve individuals of Jewish descent, and the program’s focus on outreach, education, and testing convenience are critically important to get more people screened and to understand their individual hereditary cancer or reproductive risks. We are proud to partner with them to support their screening needs as they expand.”
“We are grateful for Myriad’s partnership and the alignment of our missions to provide world class preventative genetic care to everyone, everywhere,” said Matt Goldstein, MD, PhD, CEO of jscreen. “Myriad’s quality and customer service reflect the standard we have provided to our participants for over a decade and this partnership positions us to support even more people with the powerful and live-saving tools of preventative genetics. As a pioneer of telegenetics, jscreen has focused on increasing awareness of the importance of genetic testing and improving access to carrier screening and hereditary cancer testing for more than 10 years.”
For more information and to access Myriad's genetic tests, visit www.jscreen.org, a revolutionary consumer-initiated platform where people can order genetic tests from the comfort of their own homes. Consumers simply order a test kit online, provide a saliva sample and send it back to the Myriad lab to process results.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
About jscreen™
jscreen’s mission is to ensure every Jewish adult in the United States has access to education, genetic testing and counseling to inform their reproductive options and understanding of their own hereditary cancer risks. For more than 10 years, jscreen has been a pioneer of telegenetics with deep reach and connection in Jewish communities across the United States. To learn more, visit jscreen.org.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that through the partnership, the jscreen program intends to reach hundreds of thousands of high-risk adults across the United States through targeted outreach, educational events and in-person genetic screenings and that the partnership will help the company better serve individuals of Jewish descent. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Media Contact:
Glenn Farrell
(385) 318-3718
PR@myriad.com
Investor Contact:
Matt Scalo
(801) 584-3532
IR@myriad.com
FAQ
What is the purpose of Myriad Genetics' partnership with jscreen™?
Which Myriad Genetics (MYGN) products are included in the partnership with jscreen™?
How will the Myriad Genetics (MYGN) and jscreen™ partnership reach potential patients?
What is the process for consumers to access Myriad Genetics (MYGN) tests through the jscreen™ platform?
